CBD Reduced Brain Inflammation After Traumatic Brain Injury in Rats Through a Specific Signaling Pathway

CBD significantly improved neurological deficit scores, reduced neuronal damage, and decreased blood-brain barrier permeability after TBI. It inhibited astrocyte activation, reduced inflammatory prostaglandin markers, and lowered brain injury markers S-100-beta and NSE. Blocking the EP2 receptor or PKA enzyme eliminated CBD's protective effects, confirming the PGE2-EP2-cAMP-PKA pathway as the mechanism.

Rat traumatic brain injury model using the Feeney free-fall method. CBD was administered and neurological, histological, and molecular outcomes measured. Specific pathway inhibitors (TG6-10-1 for EP2, H-89 for PKA) were used to confirm the mechanism.

Traumatic brain injury affects millions annually with limited treatment options. Identifying a specific molecular pathway through which CBD reduces brain inflammation provides a target for drug development and helps explain why CBD might be neuroprotective.

With no effective drugs currently available for secondary brain injury after TBI, CBD's ability to reduce inflammation through a defined pathway makes it a candidate for clinical investigation, especially since CBD has a favorable safety profile compared to many neuroprotective agents.

Rat model may not translate to human TBI, single injury model tested, CBD dosing and timing may not reflect clinical scenarios, pathway inhibitor studies confirm mechanism but do not guarantee clinical efficacy, no long-term outcome data